Potential Public Health and Economic Impact of the Next-Generation COVID-19 Vaccine mRNA-1283 in The Netherlands
Vaccines · 20.04.2026 · 14 (4) · 364
DOI: 10.3390/vaccines14040364 ↗Kurz gefasst
Fachartikel in der Zeitschrift Vaccines, online erschienen am 20.04.2026. Verfasst von Simon van der Pol und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Health Sciences, University Medical Center Groningen, University of Groningen, 9700RB Groningen, The Netherlands. Die Arbeit nennt 60 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Moderna Therapeutics (United States), Moderna, Inc..
Abstract (Originalsprache)
Background
COVID-19 remains a substantial public health challenge in the Netherlands. Next-generation COVID-19 vaccine, mRNA-1283, is approved in the European Union, with potential for higher relative vaccine efficacy compared with originally licensed COVID-19 vaccines.
Methods
The potential public health and economic impact of mRNA-1283 in adults ≥ 60 years and high-risk adults aged 18–59 years was modeled versus no vaccination and originally licensed mRNA-1273 and BNT162b2, adapting a published static Markov model with a 1-year time horizon. COVID-19 burden reflected two full post-pandemic seasons. Vaccine efficacy versus mRNA-1273 was based on pivotal phase 3 NextCOVE trial data; efficacy versus BNT162b2 was derived from an indirect treatment comparison. The economically justifiable price (EJP) of mRNA-1283 versus no vaccination and price premiums over existing vaccines were determined at a willingness-to-pay threshold of €50,000/quality-adjusted life-year (QALY) gained.
Results
Without COVID-19 vaccination, an estimated 460,000 infections, 23,800 hospitalizations, and 5300 deaths would occur. With current coverage, mRNA-1283 was estimated to prevent 68,000 infections, 5400 hospitalizations, and 1200 deaths, saving 9667 QALYs and over €66.5 million in treatment costs. The EJP was €238 versus no vaccination. Compared with mRNA-1273 and BNT162b2, mRNA-1283 was estimated to prevent additional burden (e.g., 1309 and 1679 hospitalizations, respectively) and was cost-effective at an incremental EJP of €62 versus mRNA-1273 and €80 versus BNT162b2.
Conclusions
The results support continued COVID-19 vaccination to mitigate the ongoing health and societal burden of SARS-CoV-2 in the Netherlands. The comparative analyses indicate that mRNA-1283 may be associated with substantial health benefits over originally licensed mRNA vaccines; consequently, its use may further improve health outcomes and economic efficiency within COVID-19 vaccination programs.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Health Sciences, University Medical Center Groningen, University of Groningen, 9700RB Groningen, The Netherlands.
- Health-Ecore, 3704HE Zeist, The Netherlands.
- Moderna, Inc., Cambridge, MA 02142, USA.
- Moderna Netherlands, 1082MC Amsterdam, The Netherlands.
- Department of Economics, Econometrics and Finance, University of Groningen, 9747AE Groningen, The Netherlands.
- Department of Management Sciences, Open University, 6401DL Heerlen, The Netherlands.
ORCID-Profile: Simon van der Pol, Ekkehard Beck, Tjalke Westra
Förderung
- Moderna Therapeutics (United States)
- Moderna, Inc.
Zitieren
APA
van der Pol, S., Beck, E., Westra, T., Postma, M., & Boersma, C. (2026). Potential Public Health and Economic Impact of the Next-Generation COVID-19 Vaccine mRNA-1283 in The Netherlands. Vaccines, 14(4), 364. https://doi.org/10.3390/vaccines14040364
Vancouver
van der Pol S, Beck E, Westra T, Postma M, Boersma C. Potential Public Health and Economic Impact of the Next-Generation COVID-19 Vaccine mRNA-1283 in The Netherlands. Vaccines. 2026;14(4):364. doi:10.3390/vaccines14040364
BibTeX
@article{vanderPol2026,
author = {van der Pol, Simon and Beck, Ekkehard and Westra, Tjalke and Postma, Maarten and Boersma, Cornelis},
title = {Potential Public Health and Economic Impact of the Next-Generation COVID-19 Vaccine mRNA-1283 in The Netherlands},
journal = {Vaccines},
year = {2026},
volume = {14},
number = {4},
pages = {364},
doi = {10.3390/vaccines14040364}
}
EUVIMED